GRACE :: Lung Cancer

DDR2 Mutations in Squamous Cell Lung Cancer

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial

The following piece is from the University of Colorado, where Dr. Camidge and some others there are leading a very novel trial for a small molecularly defined subgroup with specific biomarkers related to fibroblast growth factor receptor-1 (FGFR1) are potential candidates for a trial just launching now with the agent ponatinib, a tyrosine kinase inhibitor (TKI) that hits many targets.  This is a new approach, trying to reach an audience of patients through the internet, and I’m hopeful it will succeed in giving patients a novel treatment opportunity and in moving research along faster.

————————————- Continue reading

Immunotherapy: What Has a Year’s Experience Taught Us Since ASCO 2013?

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

RADIANT and SELECT: Is Adjuvant Erlotinib Effective in Early-Stage Lung Cancer?

Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Erlotinib for early-stage lung cancer.

Disease-free Survival: EGFR+ Subgroup

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

CREST Trial Design

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content


Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources